

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

F. Fontanesi reports the following:

Employer: University of Miami

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Flavia Fontanesi

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: January 21, 2024

Disclosure Updated Date: January 21, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

A. Fornoni reports the following:

Employer: University of Miami; Consultancy: Dimerix, Travere, Bayer, DinaQOR; Ownership Interest: I am CSO and Vice-President of L&F Health LLC.; I am shareholder for Zyversa Therapeutics; I am shareholder of River 3 Renal Corp; I am shareholder of UpToDate; Research Funding: Aurinia, Pfizer, Travere; Patents or Royalties: Patent on the use of cyclodextrin for the treatment of kidney diseases.; Patent on the use of small molecule inducers of cholesterol efflux.; I own shares in Zyversa Therapeutics and R3R.; and Other Interests or Relationships: I am inventor on 5 pending US patents and one published patent.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Alessia Fornoni

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: January 22, 2024

Disclosure Updated Date: September 5, 2023

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Ge has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Mengyuan Ge

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: March 6, 2024

Disclosure Updated Date: March 6, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

J. Kim reports the following:

Research Funding: NIDDK K01

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Jin Ju Kim

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: March 5, 2024

Disclosure Updated Date: May 22, 2023

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

S. Merscher reports the following:

Employer: University of Miami; Ownership Interest: Zyversa Therapeutics, Inc.; Research Funding: Aurinia Pharmaceuticals; Pfizer; Patents or Royalties: I am Co-inventor on several pending and issued patents. I have an indirect equity interest in, and potential patent licensing income from, ZyVersa Therapeutics, Inc. by virtue of assignment and licensure of a patent estate.; and Advisory or Leadership Role: Review Editor for Frontiers in Medicine, section nephrology; Associate Editor for Frontiers in Medicine, section Nephrology.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Sandra M. Merscher

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: March 5, 2024

Disclosure Updated Date: March 5, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

J. Molina David has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Judith T. Molina David

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: March 19, 2024

Disclosure Updated Date: March 19, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

R. Njeim has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Rachel Njeim

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: January 21, 2024

Disclosure Updated Date: January 21, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Pieper reports the following:

Employer: Boehringer Ingelheim Pharma GmbH & Co. KG; Research Funding: Boehringer Ingelheim Pharma GmbH & Co. KG; and Patents or Royalties: Boehringer Ingelheim Pharma GmbH & Co. KG.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Michael P. Pieper

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: April 2, 2024

Disclosure Updated Date: April 2, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

K. Sharma reports the following:

Employer: University of Texas Health San Antonio; South Texas VA HealthCare System; Consultancy: Otsuka, Bayer, Cara Therapeutics; Ownership Interest: SygnaMap; Research Funding: Boehringer Ingelheim; Honoraria: Pfizer; Patents or Royalties: University of Texas Health San Antonio; Advisory or Leadership Role: DSMB for Cara Therapeutics. Founder, SygnaMap. Reata; and Other Interests or Relationships: Texas Renal Coalition, ex-board member of Texas Kidney Foundation.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Kumar Sharma

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: April 1, 2024

Disclosure Updated Date: March 27, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

I. Tamayo has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Ian M. Tamayo

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: March 26, 2024

Disclosure Updated Date: May 19, 2023

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationship or commitment held by myself and/or my spouse/partner in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

G. Zhang has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Guanshi Zhang

Manuscript ID: K360-2023-000660R1

Manuscript Title: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome

Date of Completion: March 4, 2024

Disclosure Updated Date: March 4, 2024